Travere CFO Sells Shares in 10b5‑1 Plan While Buying Big Option Block: What Investors Should Watch for This Biotech Stock
Explore how Travere Therapeutics’ insider sales and option purchases shape investor outlook—balancing short‑term liquidity with long‑term growth potential.
3 minutes to read
